Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous lymphocyte infusion
- Development stage
- Phase 2
- Lead developer
- Moffitt Cancer Center
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous lymphocyte infusion (ALI) is an adoptive cell therapy developed by the H. Lee Moffitt Cancer Center and Research Institute for the treatment of metastatic melanoma. The procedure involves the ex vivo expansion of a patient's own lymphocytes, which are then re-infused into the patient to bolster the immune system's ability to recognize and destroy tumor cells. In clinical protocols (such as NCT00338377), ALI is typically administered following a lymphodepleting conditioning regimen of fludarabine and in combination with a dendritic cell vaccine pulsed with melanoma-associated antigens, including MART-1, gp100, tyrosinase, and NY-ESO-1. This multi-component approach is designed to create a favorable environment for the infused lymphocytes to proliferate and mount a targeted T-cell response against malignant melanoma cells.
- Other names
- autologous lymphocyte therapyadoptive lymphocyte infusion
02
Targets
MART-1/HLA-A*02:01 (Melanoma-associated antigen (Melanoma antigen recognized by T cells 1, Melanocyte protein PMEL, Tyrosinase) peptide-HLA-A*02:01 complex)New York esophageal squamous cell carcinoma 1-derived peptide presented on Human Leukocyte Antigen class ITYR/HLA-A*02:01 (Human leukocyte antigen A*02:01–Tyrosinase peptide complex)PMEL (Melanocyte Protein PMEL)
Beyond the preview
Go deeper on autologous lymphocyte infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous lymphocyte infusion.